Previous 10 | Next 10 |
Expects to initiate its planned pharmacokinetic (PK) clinical trials before year end 2020 This program will be reviewed under the 505(b)(2) regulatory approval pathway AQST-108 may address an unmet need in patients requiring rescue medication for anaphylaxis WARREN, N.J., June 29, 20...
WARREN, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management wi...
WARREN, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that due to the p...
Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +161% on positive Tc99m tilmanocept data in rheumatoid arthritis. More news on: Navidea Biopharmaceuticals, Inc., Medigus Ltd., Digirad Corporation, Stocks on the move, , Read more ...
The FDA approves Sunovion's Kynmobi (apomorphine hydrochloride) sublingual film for the treatment of OFF episodes in Parkinson's disease patients. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
WARREN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced plans to advance it...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Aquestive Therapeutics, Inc. (HEI) Q1 2020 Earnings Conference Call May 07, 2020, 08:00 AM ET Company Participants Stephanie Carrington - Westwicke, IR Keith Kendall - CEO, President and Director John Maxwell - CFO Daniel Barber - COO Ken Marshall - CCO Conference Call Par...
WARREN, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management wil...
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q1 2020 Earnings Call May 6, 2020 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distri...
Clearwater Paper Corporation (CLW) is expected to report for Q2 2024 Amgen Inc. (AMGN) is expected to report $4.93 for Q2 2024 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.47 for Q2 2024 Axon Enterprise Inc. (AXON) is expected to report $0.55 for Q2 2024 Ame...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...